GENFIT refocuses the development of VS-01 on a new pathology

On September 19, 2025, GENFIT announced the discontinuation of its VS-01 program in acute-on-chronic liver failure (ACLF). This decision follows a serious adverse event reported during a clinical trial related to peritonitis. Although the Independent Monitoring Committee suggested continuing the study with more data, GENFIT chose to discontinue the program, focusing instead on urea cycle disorders (UCD).

This strategy will potentially provide a therapeutic option for children suffering from acute hyperammonemic crises. GENFIT continues to explore other treatments for ACLF, with four assets in development. Furthermore, the company expects to reduce its operating expenses while continuing to advance projects such as GNS561 for cholangiocarcinoma.